全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...
PLOS ONE  2012 

Identification of BC005512 as a DNA Damage Responsive Murine Endogenous Retrovirus of GLN Family Involved in Cell Growth Regulation

DOI: 10.1371/journal.pone.0035010

Full-Text   Cite this paper   Add to My Lib

Abstract:

Genotoxicity assessment is of great significance in drug safety evaluation, and microarray is a useful tool widely used to identify genotoxic stress responsive genes. In the present work, by using oligonucleotide microarray in an in vivo model, we identified an unknown gene BC005512 (abbreviated as BC, official full name: cDNA sequence BC005512), whose expression in mouse liver was specifically induced by seven well-known genotoxins (GTXs), but not by non-genotoxins (NGTXs). Bioinformatics revealed that BC was a member of the GLN family of murine endogenous retrovirus (ERV). However, the relationship to genotoxicity and the cellular function of GLN are largely unknown. Using NIH/3T3 cells as an in vitro model system and quantitative real-time PCR, BC expression was specifically induced by another seven GTXs, covering diverse genotoxicity mechanisms. Additionally, dose-response and linear regression analysis showed that expression level of BC in NIH/3T3 cells strongly correlated with DNA damage, measured using the alkaline comet assay,. While in p53 deficient L5178Y cells, GTXs could not induce BC expression. Further functional studies using RNA interference revealed that down-regulation of BC expression induced G1/S phase arrest, inhibited cell proliferation and thus suppressed cell growth in NIH/3T3 cells. Together, our results provide the first evidence that BC005512, a member from GLN family of murine ERV, was responsive to DNA damage and involved in cell growth regulation. These findings could be of great value in genotoxicity predictions and contribute to a deeper understanding of GLN biological functions.

References

[1]  Choy WN (2001) Genetic toxicology and cancer risk assessment. New York: Informa HealthCare. pp. 93–139.
[2]  Kirkland D, Speit G (2008) Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens III. Appropriate follow-up testing in vivo. Mutat Res 654: 114–132.
[3]  Ellinger-Ziegelbauer H, Stuart B, Wahle B, Bomann W, Ahr HJ (2005) Comparison of the expression profiles induced by genotoxic and nongenotoxic carcinogens in rat liver. Mutat Res 575: 61–84.
[4]  Thomas RS, O'Connell TM, Pluta L, Wolfinger RD, Yang L, et al. (2007) A comparison of transcriptomic and metabonomic technologies for identifying biomarkers predictive of two-year rodent cancer bioassays. Toxicol Sci 96: 40–46.
[5]  Van Hummelen P, Sasaki J (2010) State-of-the-art genomics approaches in toxicology. Mutat Res 705: 165–171.
[6]  Scott DJ, Devonshire AS, Adeleye YA, Schutte ME, Rodrigues MR, et al. (2011) Inter- and intra-laboratory study to determine the reproducibility of toxicogenomics datasets. Toxicology 290: 50–58.
[7]  Magkoufopoulou C, Claessen SM, Jennen DG, Kleinjans JC, van Delft JH (2011) Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis 26: 593–604.
[8]  Ellinger-Ziegelbauer H, Aubrecht J, Kleinjans JC, Ahr HJ (2009) Application of toxicogenomics to study mechanisms of genotoxicity and carcinogenicity. Toxicol Lett 186: 36–44.
[9]  Yélamos J, Monreal Y, Saenz L, Aguado E, Schreiber V, et al. (2006) PARP-2 deficiency affects the survival of CD4+ CD8+ double-positive thymocytes. EMBO J 25: 4350.
[10]  Boeke JD, Stoye JP (1997) Retrotransposons, endogenous retroviruses, and the evolution of retroelements. pp. 343–435. Retroviruses Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
[11]  Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, et al. (2001) Initial sequencing and analysis of the human genome. Nature 409: 860–921.
[12]  Waterston RH, Lindblad-Toh K, Birney E, Rogers J, Abril JF, et al. (2002) Initial sequencing and comparative analysis of the mouse genome. Nature 420: 520–562.
[13]  Dupressoir A, Vernochet C, Bawa O, Harper F, Pierron G, et al. (2009) Syncytin-A knockout mice demonstrate the critical role in placentation of a fusogenic, endogenous retrovirus-derived, envelope gene. Proc Natl Acad Sci U S A 106: 12127–12132.
[14]  Wang T, Zeng J, Lowe CB, Sellers RG, Salama SR, et al. (2007) Species-specific endogenous retroviruses shape the transcriptional network of the human tumor suppressor protein p53. Proc Natl Acad Sci U S A 104: 18613–18618.
[15]  Ponferrada VG, Mauck BS, Wooley DP (2003) The envelope glycoprotein of human endogenous retrovirus HERV-W induces cellular resistance to spleen necrosis virus. Arch Virol 148: 659–675.
[16]  Balada E, Ordi-Ros J, Vilardell-Tarres M (2009) Molecular mechanisms mediated by human endogenous retroviruses (HERVs) in autoimmunity. Rev Med Virol 19: 273–286.
[17]  Ruprecht K, Mayer J, Sauter M, Roemer K, Mueller-Lantzsch N (2008) Endogenous retroviruses and cancer. Cell Mol Life Sci 65: 3366–3382.
[18]  Hsieh LL, Hsiao WL, Peraino C, Maronpot RR, Weinstein IB (1987) Expression of retroviral sequences and oncogenes in rat liver tumors induced by diethylnitrosamine. Cancer Res 47: 3421–3424.
[19]  Dragani TA, Manenti G, Porta GD, Weinstein IB (1987) Factors influencing the expression of endogenous retrovirus-related sequences in the liver of B6C3 mice. Cancer Res 47: 795–798.
[20]  Itin A, Keshet E (1986) A novel retroviruslike family in mouse DNA. J Virol 59: 301–307.
[21]  Ribet D, Harper F, Esnault C, Pierron G, Heidmann T (2008) The GLN family of murine endogenous retroviruses contains an element competent for infectious viral particle formation. J Virol 82: 4413–4419.
[22]  Obata MM, Khan AS (1988) Structure, distribution, and expression of an ancient murine endogenous retroviruslike DNA family. J Virol 62: 4381–4386.
[23]  Suzuki T, Itoh T, Hayashi M, Nishikawa Y, Ikezaki S, et al. (1996) Organ variation in the mutagenicity of dimethylnitrosamine in Big Blue mice. Environ Mol Mutagen 28: 348–353.
[24]  Abbas T, Dutta A (2009) p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 9: 400–414.
[25]  Bates S, Rowan S, Vousden KH (1996) Characterisation of human cyclin G1 and G2: DNA damage inducible genes. Oncogene 13: 1103.
[26]  Kohany O, Gentles AJ, Hankus L, Jurka J (2006) Annotation, submission and screening of repetitive elements in Repbase: RepbaseSubmitter and Censor. BMC Bioinformatics 7: 474.
[27]  Beranek DT (1990) Distribution of methyl and ethyl adducts following alkylation with monofunctional alkylating agents. Mutat Res 231: 11–30.
[28]  Olive PL, Banáth JP (2006) The comet assay: a method to measure DNA damage in individual cells. Nat Protoc 1: 23–29.
[29]  Sackett DL, Varma JK (1993) Molecular mechanism of colchicine action: induced local unfolding of beta-tubulin. Biochemistry 32: 13560–13565.
[30]  Salmon ED, Wolniak SM (1984) Taxol stabilization of mitotic spindle microtubules: analysis using calcium-induced depolymerization. Cell Motil 4: 155–167.
[31]  Fenech M (2000) The in vitro micronucleus technique. Mutat Res 455: 81–95.
[32]  Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S (2004) Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 73: 39–85.
[33]  Hohenadl C, Germaier H, Walchner M, Hagenhofer M, Herrmann M, et al. (1999) Transcriptional activation of endogenous retroviral sequences in human epidermal keratinocytes by UVB irradiation. J Invest Dermatol 113: 587–594.
[34]  Storer RD, Kraynak AR, McKelvey TW, Elia MC, Goodrow TL, et al. (1997) The mouse lymphoma L5178Y Tk+/? cell line is heterozygous for a codon 170 mutation in the p53 tumor suppressor gene. Mutat Res 373: 157–165.
[35]  Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, et al. (1999) A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 285: 1733–1737.
[36]  Hendriks G, Atallah M, Morolli B, Calleja F, Ras-Verloop N, et al. (2012) The ToxTracker assay: novel GFP reporter systems that provide mechanistic insight into the genotoxic properties of chemicals. Toxicol Sci 125: 285–298.
[37]  Hendriks G, Atallah M, Raamsman M, Morolli B, van der Putten H, et al. (2011) Sensitive DsRed fluorescence-based reporter cell systems for genotoxicity and oxidative stress assessment. Mutat Res 709–710: 49–59.
[38]  Westerink WM, Stevenson JC, Horbach GJ, Schoonen WG (2010) The development of RAD51C, Cystatin A, p53 and Nrf2 luciferase-reporter assays in metabolically competent HepG2 cells for the assessment of mechanism-based genotoxicity and of oxidative stress in the early research phase of drug development. Mutat Res 696: 21–40.
[39]  Hastwell PW, Chai LL, Roberts KJ, Webster TW, Harvey JS, et al. (2006) High-specificity and high-sensitivity genotoxicity assessment in a human cell line: validation of the GreenScreen HC GADD45a-GFP genotoxicity assay. Mutat Res 607: 160–175.
[40]  Tsichlis PN, Bear SE (1991) Infection by mink cell focus-forming viruses confers interleukin 2 (IL-2) independence to an IL-2-dependent rat T-cell lymphoma line. Proc Natl Acad Sci U S A 88: 4611–4615.
[41]  Li JP, D'Andrea AD, Lodish HF, Baltimore D (1990) Activation of cell growth by binding of Friend spleen focus-forming virus gp55 glycoprotein to the erythropoietin receptor. Nature 343: 762–764.
[42]  Eisen MB, Spellman PT, Brown PO, Botstein D (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 95: 14863–14868.
[43]  Honma M, Zhang LZ, Sakamoto H, Ozaki M, Takeshita K, et al. (1999) The need for long-term treatment in the mouse lymphoma assay. Mutagenesis 14: 23–29.
[44]  Fenech M (2007) Cytokinesis-block micronucleus cytome assay. Nat Protoc 2: 1084–1104.
[45]  Antoccia A, Tanzarella C, Modesti D, Degrassi F (1993) Cytokinesis-block micronucleus assay with kinetochore detection in colchicine-treated human fibroblasts. Mutat Res 287: 93–99.
[46]  Okada N, Honda A, Kawabata M, Yajima N (1997) Sodium phenobarbital-enhanced mutation frequency in the liver DNA of lacZ transgenic mice treated with diethylnitrosamine. Mutagenesis 12: 179–184.
[47]  (1996) Organ variation in the mutagenicity of ethylnitrosourea in Muta mouse: results of the collaborative study on the transgenic mutation assay by JEMS/MMS. The Collaborative Study Group for the Transgenic Mouse Mutation Assay Mammalian Mutagenesis Study Group of the Environmental Mutagen Society of Japan. Environ Mol Mutagen 28: 363–375.
[48]  Suzuki T, Itoh S, Nakajima M, Hachiya N, Hara T (1999) Target organ and time-course in the mutagenicity of five carcinogens in MutaMouse: a summary report of the second collaborative study of the transgenic mouse mutation assay by JEMS/MMS. Mutat Res 444: 259–268.
[49]  Ohsawa K, Hirano N, Sugiura M, Nakagawa S, Kimura M (2000) Genotoxicity of o-aminoazotoluene (AAT) determined by the Ames test, the in vitro chromosomal aberration test, and the transgenic mouse gene mutation assay. Mutat Res 471: 113–126.
[50]  Leavitt SA, George MH, Moore T, Ross JA (2008) Mutations induced by benzo[a]pyrene and dibenzo[a,l]pyrene in lacI transgenic B6C3F1 mouse lung result from stable DNA adducts. Mutagenesis 23: 445–450.
[51]  Pommier Y (2006) Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 6: 789–802.
[52]  Latour I, Demoulin JB, Buc-Calderon P (1995) Oxidative DNA damage by t-butyl hydroperoxide causes DNA single strand breaks which is not linked to cell lysis. A mechanistic study in freshly isolated rat hepatocytes. FEBS Lett 373: 299–302.
[53]  Rink SM, Lipman R, Alley SC, Hopkins PB, Tomasz M (1996) Bending of DNA by the mitomycin C-induced, GpG intrastrand cross-link. Chem Res Toxicol 9: 382–389.
[54]  Baldwin EL, Osheroff N (2005) Etoposide, topoisomerase II and cancer. Curr Med Chem Anticancer Agents 5: 363–372.
[55]  Goodsell DS (2006) The molecular perspective: cisplatin. Oncologist 11: 316–317.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133